Biotechnology
Cesca Therapeutics reports wider net loss for FY18 as sales fall
Cesca Therapeutics (KOOL) Monday reported a wider net loss for fiscal 2018 when revenues of the biotechnology firm declined sharply.…
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the…
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after…
Four cheap biotech stocks to buy
In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic…
Earnings: Array BioPharma delivers strong Q2 results, investors cheer
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of…
Earnings preview: HIV to drive topline growth for Gilead Sciences in Q4
Biotechnology company Gilead Sciences (GILD) is scheduled to report fourth-quarter earnings results after the closing bell on Monday, February 4.…
Cambrex Corp. completes acquisition of Avista Pharma solutions
Life sciences company Cambrex Corp. (CBM) Wednesday completed its previously announced acquisition of Avista Pharma Solutions, a biotech firm engaged…
Avid Bioservices Q2 loss narrows despite lower revenues; reaffirms outlook
Avid Bioservices (CDMO) reported a narrower net loss for the second quarter of 2019, helped by a sharp decline in…
Earnings Preview: Q2 results may set the tone for Avid Bioservices’ recovery
Avid Bioservices (CDMO), a contract manufacturer in the biotechnology industry, is scheduled to release its second-quarter financial results Monday after…